REFERENCES

1. Larner AJ. Correlation or limits of agreement? Applying the Bland-Altman approach to the comparison of cognitive screening instruments. Dement Geriatr Cogn Disord 2016;42:247-54.

2. Kleine-Borgmann J, Bingel U. Nocebo effects: neurobiological mechanisms and strategies for prevention and optimizing treatment. Int Rev Neurobiol 2018;138:271-83.

3. Ren Y, Xu F. How patients be counseled on adverse drug reactions: avoiding the nocebo effect. Res Social Adm Pharm 2018; doi: 10.1016/j.sapharm.2018.04.007.

4. Beran RG, Hegazi Y, Schwartz RS, Cordato DJ. Rebound exacerbation multiple sclerosis following cessation of oral treatment. Mult Scler Relat Disord 2013;2:252-5.

5. Igra MS, Paling D, Wattjes MP, Connolly DJA, Hoggard N. Multiple sclerosis update: use of MRI for early diagnosis, disease monitoring and assessment of treatment related complications. Br J Radiol 2017;90:20160721.

6. Mulero P, Neri MJ, Rodriguez M, Arenillas JF, Téllez N. Immune reconstitution inflammatory syndrome and natalizumab - is it possible before removing the drug? Mult Scler Relat Disord 2014;3:659-61.

Neuroimmunology and Neuroinflammation
ISSN 2349-6142 (Online) 2347-8659 (Print)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/